A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS

NCT02587806 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

BIOLOGICAL: Autologous Bone Marrow-Derived Mononuclear Stem Cells
OTHER: Liberation therapy

Sponsor

Novo Cellular Medicine Institute LLP